Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial

BA Borlaug, YNV Reddy, A Braun, H Sorimachi… - Circulation, 2023 - Am Heart Assoc
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …
被引用次数：22 相关文章

Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial

BA Borlaug, YNV Reddy, A Braun, H Sorimachi… - 2023 - pubmed.ncbi.nlm.nih.gov
Background Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …

Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial

BA Borlaug, YNV Reddy, A Braun… - …, 2023 - portal.findresearcher.sdu.dk
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …

Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial

BA Borlaug, YNV Reddy, AS Amanda Braun… - Circulation, 2023 - Am Heart Assoc
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …

Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.

BA Borlaug, YNV Reddy, A Braun, H Sorimachi… - Circulation, 2023 - europepmc.org
Background Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …

Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial

BA Borlaug, YNV Reddy, A Braun… - …, 2023 - mayoclinic.elsevierpure.com
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …